Brant Inman, MD

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Patients with metastatic bladder cancer whose tumors did not respond to chemotherapy should consider using one of the checkpoint inhibitors, states Inman.

The other situation is for patients who are ineligible for cisplatin. According to Inman, if a patient cannot receive cisplatin, the best choice is to consider a checkpoint inhibitor.

Videos

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

There are not currently good biomarkers for immunotherapy, explains Inman. However, the molecular subtypes of bladder cancer can predict response to immunotherapy.

According to Inman, these biomarkers are more telling about the biology of the tumor, rather than the response to a specific treatment.

Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.

Although there have been many trials with chemotherapy combinations, there has not been much progress seen beyond gemcitabine plus cisplatin or with the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), says Inman.

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.
 

Dr. Inman Discusses the Role of Chemotherapy in Bladder Cancer

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the biology of bladder cancer.

Bladder cancer is being better understood with the utilization of genome sequencing and RNA sequencing, both of which have allowed for this disease to be categorized into several different molecular subtypes.

Tests to check for these subtypes will become important in the future, Inman says, as it will help guide treatment for patients.

Author | Brant Inman, MD

Articles

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

Dr. Inman Discusses the Role of Chemotherapy in Bladder Cancer

Dr. Inman Discusses the Biology of Bladder Cancer